Top 7 China Gene Therapy Companies 2025
China's gene therapy sector has grown rapidly, with over 100 companies developing gene replacement, gene editing, and cell-based gene therapies. The country has approved multiple CAR-T cell therapies and has dozens of gene therapy candidates in clinical trials. China's large patient population, growing biotech investment, and improving regulatory framework have created favorable conditions for gene therapy development. The market is projected to exceed $5 billion by 2027, with companies focusing on hematology, oncology, ophthalmology, and rare genetic diseases.
Fosun Kite Biotechnology (复星凯特)
Approved CAR-T: Yescarta China
Fosun Kite, a joint venture between Fosun Pharma and Kite Pharma (Gilead), brought Yescarta (axicabtagene ciloleucel) to China as the country's first approved CAR-T cell therapy. The company manufactures CAR-T products at its Shanghai facility and has expanded access through hospital partnerships. Fosun Kite is developing next-generation CAR-T therapies with improved manufacturing processes and broader indications including solid tumors.
Juventas Cell Therapy (九天生物)
Clinical programs: 8+
Juventas (formerly Ninebio) is a leading Chinese gene therapy company focused on AAV-based gene therapies for neurological and ocular diseases. The company's pipeline includes treatments for Parkinson's disease, spinal muscular atrophy, and inherited retinal diseases. Juventas has developed proprietary AAV capsids with improved tissue targeting and reduced immunogenicity. The company has raised over $200 million and operates GMP manufacturing facilities in Shanghai and Hangzhou.
Bioray Laboratories
Pipeline: 10+ gene therapy candidates
Bioray has expanded from agricultural biotechnology into human gene therapy, developing AAV-based treatments for inherited diseases. The company's gene therapy pipeline targets rare genetic disorders including hemophilia, lysosomal storage diseases, and neuromuscular conditions. Bioray leverages its CRISPR gene editing capabilities for next-generation gene therapies that can correct mutations rather than simply deliver functional gene copies.
Innovent Biologics (信达生物)
CAR-T programs: 3+
Innovent has entered the gene therapy space with CAR-T and gene-edited cell therapy programs targeting hematological malignancies and solid tumors. The company leverages its existing antibody development and clinical trial infrastructure to accelerate gene therapy development. Innovent's gene therapy candidates incorporate novel technologies including dual-targeting CARs, universal CAR-T cells, and gene-edited allogeneic cell therapies to improve safety and reduce manufacturing costs.
Legend Biotech (传奇生物)
Revenue: $1B+ (Carvykti)
Legend Biotech's Carvykti (ciltacabtagene autoleucel) is one of the most successful CAR-T therapies globally, approved for multiple myeloma in major markets. The company is developing next-generation BCMA-targeted and dual-targeting CAR-T therapies. Legend's partnership with Johnson & Johnson's Janssen division provides commercial infrastructure. The company is also exploring gene editing approaches to create off-the-shelf allogeneic CAR-T products.
Hutchmed (和记黄埔医药)
Pipeline: 15+ oncology programs
Hutchmed integrates gene therapy approaches into its broader oncology drug development platform. The company is developing oncolytic virus therapies and gene-modified cell therapies targeting solid tumors. Hutchmed's drug discovery platform uses genetic profiling to identify patient populations most likely to benefit from targeted therapies. The company has multiple gene therapy candidates in preclinical development for gastrointestinal and liver cancers.
United Gene Group (联合基因)
Genetic tests performed: 5M+
United Gene Group is one of China's earliest genetic medicine companies, combining genetic testing services with gene therapy development. The company provides comprehensive genetic screening for disease risk, pharmacogenomics, and prenatal diagnosis. Its gene therapy research focuses on monogenic diseases prevalent in the Chinese population. United Gene's extensive genetic database from testing services provides valuable information for therapy target identification and patient stratification.
Comparison Table
| Company | Therapy Type | Key Product | Indication | Clinical Stage | Manufacturing | Global Presence |
|---|---|---|---|---|---|---|
| Fosun Kite | CAR-T | Yescarta | Lymphoma | Approved | Shanghai GMP | China + J&J |
| Juventas | AAV gene therapy | JTK001 (Parkinson's) | Neurological | Phase 1/2 | Shanghai GMP | China |
| Bioray | AAV + CRISPR | Multiple candidates | Rare disease | Phase 1 | China | China |
| Innovent | CAR-T + gene edit | Multiple CARs | Hematological | Phase 1/2 | Suzhou GMP | China |
| Legend Biotech | CAR-T | Carvykti | Multiple myeloma | Approved | Nanjing GMP | Global |
| Hutchmed | Oncolytic virus | Multiple candidates | Solid tumors | Phase 1 | China | Global |
| United Gene | Gene therapy + testing | Comprehensive | Genetic diseases | Various | China | China |
Frequently Asked Questions
How many gene therapy products has China approved?
As of 2025, China's NMPA has approved 4 CAR-T cell therapy products: Fosun Kite's Yescarta (axicabtagene ciloleucel), JW Therapeutics' Relmacabtagene autoleucel, Bioray's Fucaso (equecabtagene autoleucel), and Legend Biotech's Carvykti (ciltacabtagene autoleucel). Several AAV-based gene therapy candidates are in late-stage clinical trials, with potential approvals expected within 1-3 years for inherited retinal diseases and hemophilia.
What are the challenges for gene therapy in China?
Key challenges include: high therapy costs (CAR-T treatments cost ¥1-1.2 million per patient), limited reimbursement coverage, manufacturing scale-up for viral vectors, AAV pre-existing immunity in the Chinese population, tissue-specific delivery for non-liver targets, and the need for long-term safety data. However, government healthcare policy is gradually expanding reimbursement for cell and gene therapies through provincial pilot programs.
How does China's gene therapy market compare globally?
China has the world's second-largest gene therapy clinical trial pipeline after the United States, with over 50 active trials. Chinese CAR-T approvals have closely followed US approvals. China's cost advantages in clinical trial operations and manufacturing make it attractive for gene therapy development. However, China lags in AAV-based gene therapy approvals and novel vector development. The growing Chinese biotech ecosystem and increasing investment are rapidly narrowing global gaps.
What gene therapy manufacturing capabilities exist in China?
China has built significant gene therapy manufacturing capacity, with GMP facilities in Shanghai, Suzhou, Nanjing, Hangzhou, and Beijing capable of producing viral vectors (AAV, lentivirus) and cell therapy products. Companies like Fosun Kite, Juventas, and Legend Biotech operate dedicated GMP manufacturing sites. China's lower labor and facility costs enable gene therapy production at 30-50% lower cost than Western markets, attracting international partnerships and contract manufacturing business.
Which genetic diseases are most targeted by Chinese companies?
Chinese gene therapy companies primarily target: hematological cancers (multiple myeloma, lymphoma, leukemia) via CAR-T, inherited retinal diseases (Leber congenital amaurosis, retinitis pigmentosa) via AAV, hemophilia A/B via AAV gene replacement, beta-thalassemia via gene editing, spinal muscular atrophy via AAV, and lysosomal storage diseases. The selection reflects China's disease burden and regulatory approval priorities, with cancer being the most commercially attractive segment.